{"id":"ccr2-antagonist","_chembl":{"chemblId":"CHEMBL273083","moleculeType":"Small molecule","molecularWeight":"593.67"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"CCR2 (C-C chemokine receptor type 2)","explanation":"CCR2 is a chemokine receptor expressed on monocytes and macrophages that binds CCL2 (MCP-1). By blocking CCR2, the drug prevents the migration of inflammatory cells to diseased tissues, potentially reducing inflammation and fibrosis in various conditions.","oneSentence":"Blocks the CCR2 receptor to prevent monocyte and macrophage recruitment to sites of inflammation."},"_scrapedAt":"2026-03-28T01:49:56.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122805,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"cenicriviroc","brand":null,"company":"Allergan/Tobira","rationale":"Dual CCR2/CCR5 antagonist for fibrotic and inflammatory diseases"},{"name":"propagermanium","brand":null,"company":"Asahi Kasei","rationale":"CCR2 antagonist investigated for inflammatory conditions"}],"description":"CCR2 antagonist is an investigational small molecule developed by Bristol-Myers Squibb that blocks the CCR2 receptor, a key mediator of inflammatory cell recruitment. It is being evaluated in Phase 2 clinical trials for potential treatment of inflammatory and fibrotic diseases.","indications":{"approved":[{"status":"investigational","condition":"Inflammatory diseases","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT03767582","phase":"PHASE1, PHASE2","title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-12-12","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma","enrollment":46},{"nctId":"NCT05025787","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.","status":"COMPLETED","sponsor":"Maurizio Fava, MD","startDate":"2021-10-25","conditions":"Knee Osteoarthritis","enrollment":55},{"nctId":"NCT05122182","phase":"PHASE2","title":"Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19","status":"TERMINATED","sponsor":"University of Sydney","startDate":"2022-01-07","conditions":"COVID-19, SARS-CoV2 Infection","enrollment":49},{"nctId":"NCT02996110","phase":"PHASE2","title":"A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-02-02","conditions":"Advanced Cancer","enrollment":182},{"nctId":"NCT01994291","phase":"PHASE2","title":"A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-11","conditions":"Macular Edema, Diabetic","enrollment":199},{"nctId":"NCT01712061","phase":"PHASE2","title":"A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-12","conditions":"Diabetic Nephropathy","enrollment":226},{"nctId":"NCT00699790","phase":"PHASE2","title":"Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-02","conditions":"Type 2 Diabetes","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":252,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BMS-741672"],"phase":"phase_2","status":"active","brandName":"CCR2 Antagonist","genericName":"CCR2 Antagonist","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}